News Sentiment
+40.2
Positive
DATA LIVE
Loading ...
Asset-specific news intelligence
Johnson & Johnson
Aggregated sentiment, estimated market impact and analysis confidence from recent articles linked to this asset. This feature is independent of the overall stock score.
All recent articles have completed sentiment assessments.
As of
Aug 21, 2026, 12:01 AM
News Sentiment
+40.2
Positive
Estimated Impact
46.0
Weighted estimate of how strongly the analyzed news may affect the asset.
Analysis Confidence
74.3
Confidence in the asset-specific article assessments, not historical model reliability.
Processing state of all articles inside the selected window.
Articles
2
Available
2
Pending
0
Failed
0
Unassessed
0
Latest analyzed article
Aug 20, 2026, 4:38 AM
Counts include only articles with an available assessment.
Positive
1
Neutral
1
Negative
0
High impact
0
Latest article
Aug 19, 2026, 2:30 PM
Showing 1–2 of 2 articles
Warren Buffett warns that investors are gambling in the current market environment with excessive speculation. The article recommends three defensive stocks that could perform well during a market correction: Johnson & Johnson, PepsiCo, and Waste Management. These companies offer stability through strong dividend growth histories, quality business models, and resilience during economic downturns.
Analysis summary
The article mentions Johnson & Johnson as one of three defensive stocks recommended by Warren Buffett during a period of market speculation. The recommendation is based on the company's stable dividend history, strong business model, and resilience in downturns, suggesting moderate positive sentiment for JNJ. However, the article does not report any new event or material development specific to J&
Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.
Analysis summary
The article compares two healthcare-focused ETFs, FHLC and IHE, without directly addressing Johnson & Johnson's specific performance, financials, or events. While JNJ is a pharmaceutical company and may be included in these ETFs, the article does not mention JNJ specifically or provide asset-specific information. The discussion of ETF performance and strategy is general and not materially relevant